Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25932179 | 0.87 | HDAC11 (0.67) | HDAC11HDAC8 | |
| SCHEMBL25932170 | 0.87 | HDAC11 (0.54) | HDAC11HDAC8KDM4EMEN1KMT2A | |
| SCHEMBL21496793 | 0.86 | HDAC11 (0.58) | HDAC11HDAC8 | |
| SCHEMBL21496689 | 0.81 | HDAC11 (0.70) | HDAC11HDAC8 | |
| SCHEMBL25932190 | 0.78 | HDAC11 (0.59) | HDAC11HDAC8KDM4ETRPA1 | |
| SCHEMBL21496854 | 0.75 | HDAC11 (0.51) | HDAC11HDAC8KDM4EKMT2AALDH1A1 | |
| SCHEMBL30039052 | 0.75 | HDAC11 (0.65) | HDAC11HDAC8 | |
| SCHEMBL21500465 | 0.75 | HDAC11 (0.65) | HDAC11HDAC8 | |
| SCHEMBL25932167 | 0.74 | HDAC11 (0.69) | HDAC11HDAC8 | |
| SCHEMBL21496843 | 0.74 | HDAC11 (0.58) | HDAC11HDAC8KDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | HDAC11 4/4885HDAC8 9/4885KDM4E 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.